Our data thus strongly suggested a model in which skeletal muscle IRF4 transcriptionally regulates FSTL1, and the latter is secreted in the liver to mediate liver metabolism through DIP2A/CD14, eventually affecting the pathology of NASH (Fig. 7j). The gene discussed is DIP2A; the disease is metabolic dysfunction-associated steatohepatitis.